Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial of Rabexiomod in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who have Previously been Treated with Methotrexate with Inadequate Response

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial of Rabexiomod in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who have Previously been Treated with Methotrexate with Inadequate Response

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rabeximod (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cyxone
  • Most Recent Events

    • 19 Jul 2019 According to a Cyxone media release, the company will announce the response from the appropriate authorities once received and make further announcements as the preparations of this clinical phase IIb trial with Rabeximod in RA advances.
    • 19 Jul 2019 According to a Cyxone media release, submissions in up to eight additional countries, including Estonia, Ukraine, Georgia and the Netherlands, will follow within the next six months. In parallel, further processes such as procuring suitable statisticians and analysts for the study data, selecting investigational sites and drug manufacturer with manufacturing authorization in Europe have been completed or are currently underway.
    • 19 Jul 2019 According to a Cyxone media release, EGeen is also involved in the preparations by ensuring localized documentation and liaising with regulatory authorities locally in the select Eastern European countries.The company is moving forward with preparations of the trial and soon enough starting patient recruitment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top